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Acid bone lysate activates TGFβ 
signalling in human oral fibroblasts
Franz Josef Strauss  1,2, Alexandra Stähli1,3, Lucian Beer4,5, Goran Mitulović  6, 
Valentina Gilmozzi1, Nina Haspel1, Gerhild Schwab1 & Reinhard Gruber  1,3
Demineralized bone matrix is a widely used allograft from which not only the inorganic mineral but also 
embedded growth factors are removed by hydrochloric acid (HCl). The cellular response to the growth 
factors released during the preparation of demineralized bone matrix, however, has not been studied. 
Here we investigated the in vitro impact of acid bone lysate (ABL) prepared from porcine cortical bone 
chips on oral fibroblasts. Proteomic analysis of ABL revealed a large spectrum of bone-derived proteins 
including TGF-β1. Whole genome microarrays and RT-PCR together with the pharmacologic blocking 
of TGF-β receptor type I kinase with SB431542 showed that ABL activates the TGF-β target genes 
interleukin 11, proteoglycan 4, and NADPH oxidase 4. Interleukin 11 expression was confirmed at 
the protein level by ELISA. Immunofluorescence and Western blot showed the nuclear localization of 
Smad2/3 and increased phosphorylation of Smad3 with ABL, respectively. This effect was independent 
of whether ABL was prepared from mandible, calvaria or tibia. These results demonstrate that TGF-β is 
a major growth factor that is removed upon the preparation of demineralized bone matrix.
Bone grafts are regularly used for augmentation in implant dentistry, oral and maxillofacial surgery, besides other 
medical fields including orthopedics and traumatology dealing with bone reconstructions1,2. Freshly prepared 
bone autografts are considered gold standard in reconstructing large and complex bone defects due to the osteo-
conductive surface and the presence of osteogenic cells that can contribute to bone formation3. Furthermore, 
growth factors released upon autograft resorption are supposed to support bone regeneration, even though evi-
dence to support this claim is poor. Similar to the resorption of autografts by osteoclasts, demineralization of 
allografts by hydrochloric acid does not only remove the mineral phase4. Hydrochloric acid also removes a frac-
tion of growth factors intrinsic to bone. The biological activity of the respective acid bone lysate (ABL), which are 
discarded upon the preparation of demineralized bone matrix, has not been characterized so far.
Bone is a rich source of growth factors including TGF-β15,6. Pioneer work of purification and characterization 
of TGF-β1 released by hydrochloric acid and other methods dates back to the 1980s6–8. With the introduction 
of proteomics, bone extraction protocols were refined9 still including demineralization of bone by hydrochloric 
acid10. The concentration of TGF-β1 with around 0.5 ng/ml in bone lysates is conserved among skeletal areas and 
gender5. In vivo, TGF-β1 is stored in a latent form and can be released and activated by osteoclasts11–13. TGF-β1 
released during bone remodeling induces migration of mesenchymal stem cells14,15 and targets osteoclasts16. 
However, the activity of TGF-β1 and other growth factors in ABL has not been studied recently.
Bioassays with TGF-β-responsive cells are appropriate to determine TGF-β activity in ABL. We previously 
used oral fibroblasts to detect TGF-β1 activity in supernatants of freshly prepared bone chips17 and enamel matrix 
derivatives18. Moreover, the adsorption of TGF-β1 from these preparations to collagen matrices commonly used 
for guided bone regeneration was determined by gene expression changes of oral fibroblasts19,20. The selection of 
genes was based on proteomic analysis and a whole genome microarray resulting in a panel of TGF-β target genes 
including interleukin 11 (IL11), proteoglycan4 (PRG4), and NADPH oxidase 4 (NOX4)21,22. Further support for 
activation of TGF-β signaling comes from phosphorylation and translocation of Smad3 into the nucleus23.
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Here we report the protein composition of ABL and determine the respective biological activity for oral fibro-
blasts. Based on a whole genome microarray and RT-PCR approach including the pharmacologic blocking of 
TGF-β receptor type I kinase with SB43154224, ABL caused a robust activation of TGF-β signaling. ABL also 
reduced the expression of osteogenic and adipogenic differentiation markers in calvaria cells and 3T3-L1 cells, 
respectively. Our findings suggest that TGF-β is among the major growth factors being discarded upon the dem-
ineralization of bone matrix.
Results
ABL contains a large spectrum of proteins including TGF-β. To understand the complexity of ABL 
with respect to a possible cellular response, a proteomic analysis was performed. In support of previous proteomic 
analysis of bone-conditioned medium (BCM)22, we detected a wide range of proteins including growth factors 
with a possible impact on cellular function (Figs 1 and 2). Proteomic analysis of ABL revealed 394 proteins includ-
ing TGF-β1 (Suppl. Table 1). Panther classified ABL proteins into 8, 12 and 7 groups according to their molecular 
function (Fig. 1a), biologic process (Fig. 1b) and cellular component (Fig. 1c), respectively. The majority of pro-
teins were linked to transporter regulator activity (46%) and catalytic activity (28.5%) (Fig. 1a). Cellular process 
and metabolic process were represented by 26.5% and 18.6% of the proteins, respectively (Fig. 1b). The majority 
of the proteins originated from cells (37.1%) and organelles (24.5%) (Fig. 1c). The presence of active TGF-β1 in 
ABL was 1.3 ± 0.2 ng/ml independent of the bone source: mandible, calvaria or tibia (Fig. 1d). According to the 
STRING analysis tool, proteins in ABL revealed multiple clusters including ribosomal protein and collagens and 
also showed TGF-β1 (Fig. 2).
ABL maintains cell viability. To evaluate the impact of ABL on cell viability, the formation of formazan was 
determined. Dose-response curves indicate that a concentration of 5% ABL is appropriate to maintain viability 
of human gingival fibroblasts (Fig. 3a). Cell viability at 5% acidy bone lysate was further confirmed by live-dead 
staining (Fig. 3b). Thus, 5% of acid bone lysate was selected to study the whole genome response in gingival 
fibroblasts.
ABL provokes changes in gene expression based on a whole genome assay. To determine the 
overall cellular response of oral fibroblasts to ABL, a whole genome gene assay was performed. Overall, 1527 
genes are changed ≥ 1.5-fold (Suppl. Table 2). Among those genes, 17 genes (IL11, NOX4, PRG4, IL33, MMP10, 
ADAMTS5, MMP13, BMP2, COMP, INHBA, AREG, COL10A1, CXCL5, PMEPA1, TSPAN13, GPR183, ESM1) 
and 1 gene (PTX3) are at least 10-fold up- and down-regulated, respectively (Table 2). To gain information on the 
significantly expressed genes, we functionally categorized them using the WEB-based Gene Stet Analysis Toolkit 
(WebGestalt) database. GO-term analysis revealed that up-regulated genes in response to ABL were associated 
with the TGF-β signaling pathway (adj. P = 0.000045; enrichment score 12.12; genes: TGF-β1; BMP2, BMP6, 
ID3, ID1, INHBA, COMP) besides other signaling pathways. Panther classified the most regulated genes into 
5, 9 and 3 groups according to their molecular function (Fig. 4a), biologic process (Fig. 4b) and cellular compo-
nent (Fig. 4c), respectively. The majority of genes were linked to binding (44.5%) and catalytic activity (22.2%) 
(Fig. 4a). Cellular process and response to stimulus were represented by 23.1% and 19.2% of the genes, respec-
tively (Fig. 4b). The majority of the genes were related to the extracellular region (50.0%) and extracellular matrix 
(37.5%) (Fig. 4c).
ABL incites changes in gene expression via activation of TGF-β signalling. In a pilot experiment 
with the gene array (n = 1), SB431542 blocked the expression of all 17 highly up-regulated genes to less than 
2-fold, except for ESM1 (3.3-fold) and CXCL5 (5.1-fold) suggesting that the TGF-β receptor I kinase mediates 
the respective effect of ABL (Suppl. Table 3). In support of the gene array, RT-PCR and immunoassay confirmed 
the increased expression of IL11, PRG4, and NOX4 by ABL and also their suppression by SB431542 (Fig. 5a). 
At protein level, ABL increased IL11 release into the cell-culture supernatant and these effects were blocked by 
SB431542 (Fig. 5b). Further proof for activation of TGF-β signalling comes from gingival fibroblasts exposed 
to ABL showing increased phosphorylation of Smad3 (Fig. 6a) and an accumulation of Smad2/3 in the nucleus 
(Fig. 6b).
ABL from various sources supports TGF-β signalling. To understand if the embryologic origin of bone 
affects the activity of the respective ABL, bone chips were prepared from the mandible, the calvaria and the 
tibia25. All three independent preparations stimulated the expression of IL11, PRG4 and NOX4 in oral fibroblasts 
(Fig. 7a). Moreover, ABL prepared by 0.1 N HCl was most effective compared to lysates obtained with 0.01 N 
(data not shown), 1.0 N HCl (Fig. 7b) and also to lysates prepared with sodium tartrate buffer at pH 4.7 (Suppl. 
Fig. 2). In support of the RT-PCR, immunoassay confirmed the higher amount of IL11 in lysates obtained with 
0.1 N (Fig. 7c).
ABL decreases osteogenic and adipogenic differentiation markers. In agreement with our pre-
vious work17, exposure of osteogenic calvaria cells and adipogenic 3T3-L1 cells to ABL caused a considerable 
decrease of the marker genes alkaline phosphatase (ALP) and osteocalcin (OC) (Fig. 8a), as well as PPARγ and 
C/EBP (Fig. 8b), respectively. Chondrogenic ATDC5 cells showed a moderate increase of SOX9 and COL10A 
(Fig. 8c). Histochemical staining of alkaline phosphatase activity confirmed the findings from gene expression 
(Fig. 8d).
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Discussion
Bone is a rich source of growth factors that are released by osteoclasts during remodeling14,15, fracture healing26, 
but also during the preparation of demineralized bone matrix. Previous immunoassays5–8 and today’s proteomic 
analysis9,10 revealed the composition of growth factors and other molecules stored within the bone matrix. If, 
however, the respective growth factors released by HCl can induce a cellular response remained unclear. The 
study described herein revealed that, although ABL contains a large spectrum of proteins including growth 
factors, all 17 genes most strongly up-regulated by ABL in oral fibroblasts, including IL11, NOX4 and PRG4, 
Figure 1. Acid bone lysate (ABL) contains a large spectrum of proteins including TGF-β. Panther analysis of 
molecular function (a) cellular component (b) and class (c) of proteins in ABL. (d) TGF-β1 immunoassay of 
different bone regions: mandible, calvaria and tibia. N = 3–5. Data represent the mean ± SD.
www.nature.com/scientificreports/
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required activation of the TGF-β receptor type I kinase. In support of TGF-β receptor type I kinase signalling, 
ABL activated phosphorylation and nuclear accumulation of Smad3. Thus, demineralization by HCl caused the 
release of TGF-β into the acid bone lysate that is biologically active based on a panel of in vitro assays.
Our findings confirm previous observations that bone is a rich source of TGF-β15–8, with a concentration of 
around 0.5 ng/ml in bone lysates of different skeletal areas5. Moreover, TGF-β being stored in the bone matrix 
in its latent form can be activated by low pH27. Also in line with our findings is that TGF-β of demineralized 
bone matrix maintains its activity28. In vital bone, TGF-β1 released by osteoclasts during bone remodeling con-
trols migration of mesenchymal stem cells14,15 and also acts on osteoclasts16. Our pioneering research shows that 
Figure 2. STRING representation of a network involving the proteins detected in ABL. Different line colors 
represent the types of evidence for the association between proteins.
www.nature.com/scientificreports/
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TGF-β1 released during the preparation of demineralized bone matrix caused a major increase of TGF-β target 
genes, including IL11, NOX4 and PRG4. Support for this conclusion comes from our findings that in the presence 
of a TGF-β receptor I kinase inhibitor, ABL failed to change gene expression. These data are in support of previous 
research on BCM21 and enamel matrix derivative19 which also induces the expression of IL11, NOX4 and PRG4 
mediated by TGF-β receptor type I kinase activity. Further confirmation for the activation of TGF-β signaling, 
comes from our observations that ABL increased phosphorylation and nuclear accumulation of Smad2/3, similar 
to research with recombinant TGF-β129. Taken together, ABL holds a TGF-β activity as indicated by our bioassays 
with oral fibroblasts.
As a consequence of the TGF-β activity, based on our gene array approach, IL11, NOX4 and PRG4 were highly 
increased in oral fibroblasts by ABL. Considering that TGF-β activity is removed from bone grafts during demin-
eralization, the question arises whether this change in gene expression has a biological or even clinical relevance. 
Clearly this is speculation but nevertheless these genes are involved in bone regeneration and wound healing. 
IL11 is a member of the IL6 family of cytokines and has been regarded as a target gene to investigate down-stream 
TGF-β signalling pathways in lung fibroblasts30, periodontal ligament and gingival fibroblasts31 and together 
with BMP-2, can accelerate bone regeneration32. NOX4 generates intracellular superoxide and also modulates 
osteoblasts BMP-2 activity33. Hydrogen peroxide34 reduces osteoblast differentiation and expression of alkaline 
phosphatase35 but it remains unclear if this mechanism explains our observations that ABL lowered osteogenic 
differentiation. PRG4 is expressed in the superficial zone of articular cartilage36 and supports endochondral bone 
formation37. Thus, considering that HCl lowers TGF-β from bone and that TGF-β target genes play a role in bone 
regeneration and remodeling, allografts likely possess a diminished capacity to use TGF-β signalling for graft 
consolidation. Moreover, whether the ABL-mediated increase of IL11, NOX4 and PRG4 expression has an impact 
on bone regeneration needs to be determined in appropriate animal models.
The clinical relevance of the present findings, therefore, may be related to the difference between bone auto-
grafts and allografts. While autografts are rich in TGF-β and other growth factors being stored in the bone matrix, 
demineralized bone matrix presumably contains only remnants of active TGF-β38. Moreover, HCl can deactivate 
pH sensitive growth factors in the demineralized bone matrix39. So overall, allografts are left with the growth 
Figure 3. Viability of primary oral fibroblast exposed to acid bone lysate (ABL). Cell viability staining of 
primary oral fibroblast upon exposure to ABL was tested by MTT assay (a) and Live-Dead staining (b). The 
results from these experiments demonstrated that stimulation with ABL at 5% is highly biocompatible with 
oral fibroblast. Live-Dead staining was done with viable cells appearing in green and dead cells in red. N = 3–5. 
Data represent the mean ± SD relative to the control. *P < 0.05, by Kruskal-Wallis test with Dunn’s multiple 
comparisons correction.
Sequence_F Sequence_R
hGAPDH aag cca cat cgc tca gac ac gcc caa tac gac caa atc c
hPRG4 cag ttg cag gtg gca tct c tcg tga ttc agc aag ttt cat c
hNOX4 tct tgg ctt acc tcc gag ga ctc ctg gtt ctc ctg ctt gg
hIL11 gga cag gga agg gtt aaa gg gct cag cac gac cag gac
mbactin cta agg cca acc gtg aaa ag acc aga ggc ata cag gga ca
mC/EBP caa gag ccg aga taa agc caa aca gtg tcc agt tca cgg ctc ag
mCol10 gca tct ccc agc acc aga cca tga acc agg gtc aag aa
mOC ctg acc tca cag atg cca ag gta gcg ccg gag tct gtt c
mPPARg atc atc tac acg atg ctg gcc ctc cct ggt cat gaa tcc ttg
mSox9 cag caa gac tct ggg caa g tcc acg aag ggt ctc ttc tc
mALP aac cca gac aca agc att cc gag aca ttt tcc cgt tca cc
Table 1. Primer sequences.
www.nature.com/scientificreports/
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factors that remain in the bone matrix while autografts that are rich in growth factors being liberated by osteo-
clasts. Can our observation now explain possible differences in the clinical behavior of autografts and allografts? 
On the one hand, TGF-β1 released during bone remodeling induces migration of mesenchymal stem cells14,15 
and targets osteoclasts16, and exogenous TGF-β supports bone regeneration in the dog humerus40. On the other 
hand, however, TGF-β inhibited bone formation in rat bone chambers41 and mandibular defects42. TGF-β sig-
nalling also drives scar formation during wound healing43. In support for the latter concept are our findings that 
ABL considerably reduced osteogenic differentiation of calvaria cells, similar to TGF-β44 and bone BCM17 in 
MC3T3E1. Moreover, BCM loaded onto a collagen membrane can reduce bone formation in rat calvaria defects45. 
Thus, the clinical relevance of the present data has to be interpreted with caution, particularly with respect to the 
role of TGF-β1 released from bone grafts during graft consolidation. It is also not known if it is the content of 
TGF-β that explains the differential healing capacity of autografts and allografts in vivo.
Many questions remain to be answered. For example, whether ABL reflects the growth factors released by 
osteoclasts during resorption of autografts. Osteoclasts work at around pH 4 and can liberate growth factors by 
demineralization and their protease activity46. Our results showed that ABL prepared with a tartrate buffer at 
pH 4.7 moderately increased the expression of IL11 and NOX4 but not of PRG4, in contrast to the robust acti-
vation of TGF-β target genes obtained with ABL prepared with 0.1 M HCl. Osteoclasts might however activate 
latent TGF-β by proteases not being simulated in our experiment11,47. Considering that bone chips release TGF-β 
activity even at a neutral pH17, it remains unclear if the tartrate buffer liberates growth factors by decalcification 
of the bone matrix. Therefore, the data have to be interpreted with caution. Furthermore, it would be interesting 
Figure 4. Acid bone lysate (ABL) provokes changes in gene expression based on gene arrays. Eighteen genes 
were at least 10-fold up- and down-regulated by ABL (Table 2). Panther analysis of molecular function  
(a) biological process (b) and cellular component (c) of most regulated genes in oral fibroblasts by ABL.
www.nature.com/scientificreports/
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to understand the response of cells other than those of the mesenchymal lineage including macrophages48 and 
endothelial cells49 that play a role during bone regeneration and thus graft consolidation. Our proteomic analysis, 
besides the work of others10, revealed a large spectrum of proteins that are released into ABL. Even though the 
most strongly regulated genes in oral fibroblasts are the consequence of TGF-β signalling, the possible cellular 
response to other growth factors and bioactive molecules within the ABL remain to be discovered. Another 
interesting approach would be to perform bone transplantation using mouse models with an osteoblast-specific 
TGF-β knock out50. This research can provide the scientific basis to refine protocols aiming to maintain growth 
factors and their activity during the preparation of allografts.
In conclusion, TGF-β is the major growth factor removed during the preparation of demineralized bone 
matrix that caused a robust activation of the respective signaling pathway in oral fibroblasts. These findings 
might provide a possible explanation to distinguish the performance of autografts and allografts at sites of bone 
augmentation.
Methods
Acid bone lysate. Bone was obtained from adult pigs within 6 h post-mortem (Fleischerei Leopold 
Hödl, Vienna, Austria). Bone chips were harvested from the mandible, calvaria, and tibia with a bone scraper 
(Hu-Friedy, Rotterdam, the Netherlands). Bone chips were washed with Dulbecco’s modified Eagle medium 
(DMEM) supplemented with antibiotics (Invitrogen Corporation, Carlsbad, CA, USA). Five grams of wet bone 
chips were incubated while being stirred with 50 ml of 0.01, 0.1 and 1.0 N HCl (10% weight/volume) or alterna-
tively with 10 mM sodium tartrate buffer (pH 4.7) at room temperature. ABL was harvested after 16 h, centri-
fuged, and pH neutralized. After another centrifugation, ABL was filtered sterile and kept frozen at −20 °C. The 
stocks were thawed immediately before each experiment.
Cell culture. Human gingiva was harvested from extracted wisdom teeth from patients who had given 
informed and written consent. An approval was obtained from the Ethics Committee of the Medical University of 
Vienna (EK NR 631/2007), Vienna, Austria. All experiments were performed in accordance with relevant guide-
lines and regulations. A total of three strains of fibroblasts were established by explant cultures and fewer than 
10 passages were used for the experiments. Calvaria-derived osteoblasts were obtained according to a standard 
Figure 5. Acid bone lysate (ABL) changes the expression of selected genes via TGF-β signaling. Addition 
of TGF- β receptor 1 kinase antagonist SB431542 to ABL blocks the expression of the selected genes (a). 
Immunoassay of IL11 supports the previous findings at the protein level (b). N = 3–5. Data represent the mean 
± SD. *P < 0.05, ***P < 0.001, by two-tailed Mann-Whitney test.
Figure 6. Acid bone lysate (ABL) activates TGF-β-Smad2/3 signaling in primary oral fibroblasts. Incubation 
of gingival fibroblasts with ABL also caused an increased phosphorylation of Smad3 (a). Representative 
immunofluorescence confirmed the translocation of Smad2/3 into the nucleus upon stimulation with ABL (b). 
Treatment with 10 ng/ml of TGF-β was used as a positive control.
www.nature.com/scientificreports/
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protocol previously described51. Briefly, mouse pups less than 5 days old were euthanized and their calvaria col-
lagenase digested through a series of sequential digestions. The first 2 digests were discarded, and the subsequent 
digests were pooled and plated. The 3T3-L1 cell line was obtained from Christian Wolfrum (ETH Zürich, Zürich, 
Switzerland). Cells were seeded at a concentration of 30,000 cells/cm² onto culture dishes one day prior to stimu-
lation. If not otherwise indicated, cells were exposed to 5% ABL in serum-free medium for 16 h. The inhibitor for 
the TGF-βRI kinase, SB431542 (Calbiochem, Merck, Billerica, MA, USA) was used at 10 µM.
Cell differentiation. For osteogenic differentiation, calvaria cells were incubated in growth medium contain-
ing 50 μg/mL ascorbic acid and 10 mM beta glycerophosphate. For adipogenic differentiation, 3T3-L1 cells were 
incubated in growth medium containing 0.5 mM 1-methyl-3-isobutylxanthine (Sigma, St. Louis, MO, USA), 1 μM 
dexamethasone (Sigma) and 1 μg/mL insulin (Calbiochem, Merck Millipore), 10 μM indomethacin (Sigma), and 
10 μM rosiglitazone (Sigma)52. Alkaline phosphatase staining was performed after 3 days. For histochemical staining 
of alkaline phosphatase, cells were fixed as indicated and incubated with a substrate solution containing naphthol 
AS-TR phosphate and fast blue BB salt (Sigma)53. After rinsing with distilled water, cultures were photographed.
Cell viability. For viability experiments, gingival fibroblasts were incubated overnight with ABL at the indi-
cated concentrations. MTT (3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma) solution at 
a final concentration of 0.5 mg/ml was added to each well of a microtiter plate (CytoOne) for 2 h at 37 °C. The 
medium was removed and formazan crystals were solubilized with dimethyl sulfoxide. Optical density was meas-
ured at 570 nm. Data were expressed as percentage of optical density in the treatment groups normalized to 
unstimulated control values. In addition, cell viability was assessed by Live-Dead staining kit from Enzo Life 
Sciences AG (Lausen, Switzerland).
Mass spectrometry. Extracted proteins were precipitated using methanol/dichloromethane and digested 
with trypsin as described earlier54 (For detail see Suppl. Methods). Briefly, precipitated proteins were dissolved 
in 50 mM triethylammonium bicarbonate, and protein concentration was determined using the DeNovix DS-11 
Microvolume Spectrophotometer (Wilmington, USA). Proteins were digested overnight at 37 °C using a trypsin/
protein ratio of 1:50. Peptides were separated on a C18 µPAC (µ-Pillar-Arrayed-Column, PharmaFluidics, Gent, 
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Figure 7. Acid bone lysate (ABL) obtained from mandible, calvaria and tibia produces an equivalent gene 
expression and TGF-β activity is highly dependent on hydrochloric acid concentration. ABL obtained from different 
sources (mandible, calvaria and tibia) produces a similar response on selected genes (a). ABL prepared with 0.1 N 
hydrochloric acid induces a higher TGF-β activity at mRNA level (b). Immunoassay of IL11 confirmed the higher 
activity of TGF-β at protein level with 0.1 N ABL (c). N = 3–5. Data represent the mean ± SD. P > 0.05, by Kruskal-
Wallis test with Dunn’s multiple comparisons correction, *P < 0.05, **P < 0.01, by two-tailed Mann-Whitney test.
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Belgium) using a nano RSLC UltiMate3000 (ThermoScientific, Vienna, Austria) separation system and detected 
with a Q-Exactive Plus Biopharma mass spectrometer.
A user defined injection program was used for sample injection and additional injector and trap column wash. 
Every sample injection was followed by two blank runs with injections of 2,2,2-trifluoroethanol for removal of 
possible samples remaining in the injector or on the trap column and prevention of carryover in the separation 
system. All database searches were performed using the in-house Mascot 2.6 and the most recent version of 
the Sus scrofa SwissProt database. All search results were refined and researched using Scaffold 4.6.5 (Proteome 
Software, Portland, OR). For the classification of the proteins the Panther system Version 13.1 (http://pantherdb.
org) was used55. To predict protein-protein interactions String database was used56 (https://string-db.org). The 
mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE57 
partner repository with the dataset identifier PXD010145 and 10.6019/PXD010145”.
Microarray analysis. Total RNA was harvested with the RNA Isolation Kit (Extractme, BLIRT S.A., Gdańsk, 
Poland). RNA quality was determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA, USA). Microarray analysis was performed using the SurePrint G3 Human Gene Expression v2 Microarray 
(Agilent Technologies, Santa Clara, CA, USA). Array image acquisition was performed with the Agilent G2505B 
Microarray Scanner and Feature Extraction software version 9.5 (Agilent). Background-corrected fluorescence 
intensity values were imported into GeneSpring v.15, log2-transformed, and then normalized by quantile normal-
ization. A filtering step was applied in order to reduce the number of multiple hypotheses. Only genes for which 
at least 100% of the values in one of the two evaluated conditions were above the 60th percentile were used for 
further analysis. Differentially expressed mRNAs were identified by paired t-tests in GeneSpring. The resulting 
p-values were corrected for multiplicity by applying Benjamini-Hochberg adjustment to all p-values calculated 
for a time point with a false discovery rate (FDR) < 5%58. Genes with an adjusted p-value < 0.05 were considered 
significant.
RT-PCR and immunoassay. Reverse transcription (RT) was performed with the SensiFAST™ cDNA 
Synthesis Kit (Bioline Reagents Ltd., London, UK). RT-PCR was done with SensiFAST™ SYBR® Kit using man-
ufacturer’s instructions (Bioline). Amplification was performed with the StepOnePlus Real-Time PCR System 
(Applied Biosystems, Life Technologies, Carlsbad, CA, USA). Primer sequences are given in Table 1. Relative gene 
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Figure 8. Acid bone lysate (ABL) decreases osteogenic and adipogenic differentiation. Exposure of osteogenic 
calvaria cells and adipogenic 3T3-L1 cells to ABL caused a considerable decrease of the marker genes alkaline 
phosphatase (ALP) and osteocalcin (OC) (a), as well as PPARγ and C/EBP (b), respectively. Chondrogenic 
ATDC5 cells showed a moderate increase of SOX9 and COL10 (c). Histochemical staining of alkaline 
phosphatase activity confirmed the findings from gene expression in osteogenic calvaria cells (d). N = 3–5. Data 
represent the mean ± SD.
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expression was calculated with the delta delta CT method. Reactions were run in duplicates. The supernatant was 
analyzed for IL11 and TGF-β1 using an immunoassay assay according to the manufacturer’s instructions (R&D 
Systems, Minneapolis, MN, USA).
Western blot. Cell extracts containing SDS buffer and protease inhibitors (PhosSTOP with cOmplete; Sigma, 
St. Louis, MO, USA) were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Whatman, 
GE Healthcare, General Electric Company, Fairfield, CT, USA). Membranes were blocked and the binding of the 
first antibody (rabbit anti-pSmad3 Ser423/425, 1:500, Abcam, ab52903, Cambridge, UK), and actin (Santa Cruz 
Biotechnology, SCBT, Santa Cruz, CA, USA) was detected with the appropriate secondary antibody directly labe-
led with near-infrared dyes (LI-COR Biosciences, Lincoln, NE, USA) and visualized with the appropriate imaging 
system (LI-COR Biosciences). Acquired images were not processed.
Immunofluorescence. Immunofluorescent analysis was performed on human gingival fibroblasts plated 
onto Millicell® EZ slides (Merck KGaA, Darmstadt, Germany) treated with ABL 5% for 30 min. Cells were fixed 
in paraformaldehyde and blocked in 1% BSA and 0.3% Triton in PBS at room temperature for 1 hour. Cells were 
subsequently incubated with Smad2/3 antibody (1:800, D7G7 XP® Rabbit mAb #8685, Cell Signaling, MA, USA) 
overnight at 4 °C. Alexa Fluor 488 secondary antibody (1:500; Anti-Rabbit, Cell signaling Technology, USA) was 
applied for 1 hour. Cells were washed and mounted onto glass slides. Fluorescent images were captured at 40x in 
oil immersion using a Zeiss Axiovert 200 M fluorescent microscope.
Statistical analysis. All experiments were repeated three to five times. Bars show the mean and standard 
deviation of the cumulative data from all experiments. Statistical analysis was based on Mann-Whitney U test 
and Kruskal-Wallis test with Dunn’s multiple comparisons correction. Analyses were performed using Prism v7 
(GraphPad Software, La Jolla, CA, USA). Significance was set at p < 0.05.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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